Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lamivudine - Takeda

Next Previous
X
Search
Drug Profile

Lamivudine - Takeda

Alternative Names: 3TC; 3TC-HBV; BCH 189; BCH 790; Epivir; Epivir-HBV; GR 103665; GR 109714X; Heptodin®; Heptovir; NGPB 21; Victron; Zeffix; Zefix

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Shire Pharmaceuticals Group
  • Developer Ajinomoto; Aspen Pharmacare; GlaxoSmithKline KK; GSK
  • Class Antiretrovirals; Deoxyribonucleosides; Dideoxynucleosides; Pyrimidine nucleosides; Small molecules
  • Mechanism of Action Nucleoside reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hepatitis B; HIV infections; Liver cirrhosis

Most Recent Events

  • 08 Jan 2019 Shire has been acquired and merged into Takeda
  • 08 Feb 2018 The US label for lamivudine carries a black box warning related to lactic acidosis and severe hepatomegaly, exacerbations of hepatitis B and different formulations of lamivudine
  • 06 Jun 2012 First generic equivalent available in United Kingdom and Italy for HIV infections

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top